Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 146 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo (Part II) Clear all

Conditions: Rheumatoid Arthritis
Interventions: Anti-TNF-alpha, Methotrexate, Placebo, RO7123520; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 32
States / cities: Anniston, Alabama • Glendale, Arizona • Mesa, Arizona + 25 more

Conditions: XMEN
Interventions: Magnesium L-threonate, Placebo, Intravenous (IV) magnesium sulfate (MgSO4); Dietary Supplement · Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Spinal Cord Injuries, Upper Extremity Paresis
Interventions: Active Vagus Nerve Stimulation, Placebo Vagus Nerve Stimulation; Device
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK1292263, GSK1292263 matching placebo, Sitagliptin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Chula Vista, California • Miami, Florida

Conditions: Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy, Neurotoxicity
Interventions: calcium gluconate, magnesium sulfate, placebo, oxaliplatin; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 404
States / cities: Fairbanks, Alaska • Antioch, California • Fairfield, California + 278 more

Conditions: Facetogenic Back Pain, Back Pain
Interventions: Allogeneic Human Mesenchymal Stem Cells (hMSCs), Placebo; Biological · Drug
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Agitation,Psychomotor, Dementia
Interventions: Sublingual film containing Dexmedetomidine, Sublingual Placebo Film; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 65 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Homestead, Florida • Miami Lakes, Florida • Springfield, Massachusetts + 2 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Placebo (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B), Placebo (Part B), CK-2017357 (Part B); Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: San Francisco, California • Jacksonville, Florida • Kansas City, Kansas + 6 more

Conditions: Diabetes Mellitus
Interventions: JTT-252 or Placebo, JTT-252; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Overland Park, Kansas • Austin, Texas

Conditions: Prostate Cancer Metastatic
Interventions: LY3023414, Enzalutamide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 36
States / cities: Homewood, Alabama • Fayetteville, Arkansas • Marina del Rey, California + 31 more

Conditions: Psoriasis
Interventions: Placebo (fasted), BI 25 mg (fasted), BI 50 mg (fasted), BI 100 mg (fasted), BI 200 mg (fasted), Placebo (fed), BI 400 mg once daily (fed), BI 200 mg twice daily, 400 mg total (fed); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 13 more

Conditions: Healthy Adults
Interventions: Dextroamphetamine, Placebo, [18F]Fallypride, [18F]-FE-PE2I; Drug · Diagnostic Test
Lead sponsor: Vanderbilt University; Other
Eligibility: 20 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hemophilic Arthropathy
Interventions: TRM-201 (Rofecoxib), Placebo; Drug
Lead sponsor: Tremeau Pharmceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 19
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 15 more

Conditions: Parkinson's Disease With Cognitive Impairments
Interventions: safinamide, placebo; Drug
Lead sponsor: Newron Pharmaceuticals SPA; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 9
States / cities: Sunnyvale, California • Jacksonville, Florida • Atlanta, Georgia + 5 more

Conditions: Melanoma
Interventions: Pembrolizumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 12 Years and older
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2033
U.S. locations: 39
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 28 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 44
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 27 more

Conditions: Bacterial Conjunctivitis
Interventions: SUM-191, Placebo; Drug
Lead sponsor: Senju USA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Controls, Alcohol Use Disorder
Interventions: Placebo, Oxytocin; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 45 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cystic Fibrosis
Interventions: PTI-428, Placebo; Drug
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 20
States / cities: Stanford, California • Altamonte Springs, Florida • Gainesville, Florida + 16 more

Conditions: Sickle Cell Disease
Interventions: ITU512, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more

Conditions: Vasomotor Symptoms, Menopausal Symptoms
Interventions: Estetrol oral tablet, Placebo oral tablet; Drug
Lead sponsor: Estetra; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 1,015 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 111
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 82 more

Conditions: Delayed Graft Function
Interventions: OPN-305, Placebo; Drug
Lead sponsor: Opsona Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 14
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 10 more

Conditions: Advanced and Metastatic Breast Cancer
Interventions: AZD2014, Palbociclib, Fulvestrant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 5
States / cities: Encinitas, California • Sarasota, Florida • Detroit, Michigan + 2 more

Conditions: Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed, HHT
Interventions: Pazopanib, Placebo oral capsule; Drug
Lead sponsor: Cure HHT; Other
Eligibility: 18 Years to 85 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • Denver, Colorado • Augusta, Georgia + 8 more

Search by objective public record fields.

A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy

Magnesium Supplementation in People With XMEN Syndrome

Targeted Plasticity Therapy for Upper Limb Rehabilitation in Spinal Cord Injuries

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain

Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

Decision Making Study in Young and Middle-Aged Adults: Part II

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis

Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)

Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function

Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)